{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:32:43Z","timestamp":1786984363350,"version":"build-2736575974"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,14]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Leukemia represents a substantial health burden globally, yet comprehensive studies of long-term mortality trends specific to Asia remain limited. Data from the Global Burden of Disease Study (GBD) 2021 for 1992 to 2021 were used to evaluate leukemia mortality across 34 Asian countries and 5 Global Burden of Disease Study subregions. The age-period-cohort (APC) model examined age, period, and cohort effects on mortality rates. Decomposition analysis quantified contributions of population aging, growth, and epidemiological changes. From 1992 to 2021, leukemia deaths in Asia increased by 18.81%, from 136,446 (95% UI: 111,167\u2013157,844) to 162,117 (95% UI: 131,232\u2013188,521), while age-standardized mortality rate (ASMR) declined from 4.96 (95% UI: 4.08\u20135.69) to 3.39 (95% UI: 2.74\u20133.94) per 100,000 (net drift: \u20131.25%, 95% CI: \u20131.35 to \u20131.15). High-income Asia Pacific showed the largest ASMR decline (net drift: \u20131.98%, 95% CI: \u22122.11 to \u22121.85), while Southeast Asia had the highest ASMR (4.33, 95% UI: 3.56\u20135.20). Acute myeloid leukemia led deaths in most subregions, except East Asia, where acute lymphoblastic leukemia predominated (34.60%). Population aging (25.46%) and growth (37.78%) drove mortality increases, while epidemiological changes reduced mortality by 44.43%. Age-period-cohort analysis revealed a U-shaped age effect, with mortality peaking in early childhood (0\u20134 years: 6.22 [95% CI: 5.86\u20136.61] per 100 000) and older adults (90\u201394 years: 21.93 [95% CI: 19.85\u201324.22] per 100,000). Period effects showed a consistent decline, most notably in High-income Asia Pacific and East Asia. Cohort effects indicated reduced mortality risks in later birth cohorts, particularly in East Asia. Although leukemia ASMR declined substantially across Asia from 1992 to 2021, the absolute number of deaths increased because of population growth and aging. Southeast Asia, where ASMR remained highest, requires strengthened diagnostic and referral systems and improved access to essential leukemia therapies. In East Asia, the predominance of ALL-related deaths warrants further investigation and broader implementation of risk-stratified ALL treatment protocols. Across Asia, leukemia control should prioritize children, older adults, subtype-specific surveillance, pediatric hematology services, and geriatric oncology care to reduce persistent regional disparities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050187","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:02:53Z","timestamp":1786730573000},"page":"e50187","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Long-term trends in mortality of leukemia in Asia from 1992 to 2021"],"prefix":"10.1097","volume":"105","author":[{"given":"Di","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Zhuji Affiliated Hospital of Wenzhou Medical University, Shaoxing, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchao","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shaoxing People\u2019s Hospital, School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxia","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shaoxing People\u2019s Hospital, School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8377-2414","authenticated-orcid":false,"given":"Di","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Zhuji Affiliated Hospital of Wenzhou Medical University, Shaoxing, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260817","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260817","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40164-025-00684-x","article-title":"Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021.","volume":"14","author":"Pan","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"R3-20260817","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia.","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"R4-20260817","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0140-6736(24)00595-6","article-title":"Chronic lymphocytic leukaemia.","volume":"404","author":"Jain","year":"2024","journal-title":"Lancet"},{"key":"R5-20260817","doi-asserted-by":"crossref","first-page":"04150","DOI":"10.7189\/jogh.14.04150","article-title":"Global burden, risk factor analysis, and prediction study of leukaemia from 1990 to 2030.","volume":"14","author":"Wang","year":"2024","journal-title":"J Glob Health"},{"key":"R6-20260817","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia.","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"R7-20260817","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia.","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"key":"R8-20260817","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years.","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"key":"R9-20260817","doi-asserted-by":"crossref","first-page":"10468","DOI":"10.18632\/aging.202809","article-title":"Global, regional, and national burdens of leukemia from 1990 to 2017: a systematic analysis of the global burden of disease 2017 study.","volume":"13","author":"Lin","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"R10-20260817","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40364-024-00649-y","article-title":"Global, regional, and national burden of acute myeloid leukemia, 1990-2021: a systematic analysis for the global burden of disease study 2021.","volume":"12","author":"Zhou","year":"2024","journal-title":"Biomark Res"},{"key":"R11-20260817","doi-asserted-by":"crossref","first-page":"111356","DOI":"10.1016\/j.isci.2024.111356","article-title":"Global, regional, and national burden of acute lymphoblastic leukemia in children: epidemiological trends analysis from 1990 to 2021.","volume":"27","author":"Hu","year":"2024","journal-title":"iScience"},{"key":"R12-20260817","doi-asserted-by":"crossref","first-page":"1329529","DOI":"10.3389\/fpubh.2023.1329529","article-title":"Global, national, and regional burden of acute myeloid leukemia among 60-89\u2009years-old individuals: insights from a study covering the period 1990 to 2019.","volume":"11","author":"Chen","year":"2023","journal-title":"Front Public Health"},{"key":"R13-20260817","doi-asserted-by":"crossref","first-page":"e084943","DOI":"10.1136\/bmjopen-2024-084943","article-title":"Temporal changes in the burden of leukaemia and lymphoma in the Australasia and Oceania regions, 2010-2019: an analysis of the Global Burden of Disease Study 2019.","volume":"14","author":"Ho","year":"2024","journal-title":"BMJ Open"},{"key":"R14-20260817","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12889-025-21428-w","article-title":"Global leukemia burden and trends: a comprehensive analysis of temporal and spatial variations from 1990-2021 using GBD (Global Burden of Disease) data.","volume":"25","author":"Huang","year":"2025","journal-title":"BMC Public Health"},{"key":"R15-20260817","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1186\/s12889-025-23469-7","article-title":"Burden of hematologic malignancies in China from 1990 to 2021: analysis from the Global Burden of Disease Study 2021.","volume":"25","author":"Shao","year":"2025","journal-title":"BMC Public Health"},{"key":"R16-20260817","doi-asserted-by":"crossref","first-page":"908955","DOI":"10.3389\/fpubh.2022.908955","article-title":"The systematic analysis and 10-year prediction on disease burden of childhood cancer in China.","volume":"10","author":"Zhu","year":"2022","journal-title":"Front Public Health"},{"key":"R17-20260817","doi-asserted-by":"crossref","first-page":"598215","DOI":"10.3389\/fpubh.2020.598215","article-title":"The current situation and future trend of leukemia mortality by sex and area in China.","volume":"8","author":"Li","year":"2020","journal-title":"Front Public Health"},{"key":"R18-20260817","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"R19-20260817","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"R20-20260817","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"R21-20260817","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)61899-6","article-title":"GBD 2010: design, definitions, and metrics.","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"key":"R23-20260817","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2307\/2060493","article-title":"A general method of decomposing a difference between two rates into several components.","volume":"15","author":"Das Gupta","year":"1978","journal-title":"Demography"},{"key":"R24-20260817","doi-asserted-by":"crossref","first-page":"102382","DOI":"10.1016\/j.arr.2024.102382","article-title":"Trends and cross-country inequalities in the global burden of osteoarthritis, 1990-2019: a population-based study.","volume":"99","author":"Cao","year":"2024","journal-title":"Ageing Res Rev"},{"key":"R25-20260817","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.pu.12.050191.002233","article-title":"Understanding the effects of age, period, and cohort on incidence and mortality rates.","volume":"12","author":"Holford","year":"1991","journal-title":"Annu Rev Public Health"},{"key":"R26-20260817","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jare.2021.07.012","article-title":"Epidemiological and sociodemographic transitions of female breast cancer incidence, death, case fatality and DALYs in 21 world regions and globally, from 1990 to 2017: an age-period-cohort analysis.","volume":"37","author":"Mubarik","year":"2022","journal-title":"J Adv Res"},{"key":"R27-20260817","doi-asserted-by":"crossref","first-page":"106250","DOI":"10.1016\/j.jinf.2024.106250","article-title":"Global temporal trends and projections of acute hepatitis E incidence among women of childbearing age: age-period-cohort analysis 2021.","volume":"89","author":"Huang","year":"2024","journal-title":"J Infect"},{"key":"R28-20260817","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s40471-018-0174-8","article-title":"Use of age-period-cohort analysis in cancer epidemiology research.","volume":"5","author":"Murphy","year":"2018","journal-title":"Curr Epidemiol Rep"},{"key":"R29-20260817","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/sim.7519","article-title":"Correlated poisson models for age-period-cohort analysis.","volume":"37","author":"Chernyavskiy","year":"2018","journal-title":"Stat Med"},{"key":"R30-20260817","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1158\/1055-9965.EPI-14-0300","article-title":"A web tool for age-period-cohort analysis of cancer incidence and mortality rates.","volume":"23","author":"Rosenberg","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R31-20260817","doi-asserted-by":"crossref","first-page":"102996","DOI":"10.1016\/j.eclinm.2024.102996","article-title":"Global assessment of leukemia care quality: insights from the quality of care index (QCI) from 1990 to 2021.","volume":"79","author":"Pan","year":"2025","journal-title":"EClinicalMedicine"},{"key":"R32-20260817","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.drudis.2018.05.040","article-title":"Advances in treatment formulations for acute myeloid leukemia.","volume":"23","author":"Briot","year":"2018","journal-title":"Drug Discov Today"},{"key":"R33-20260817","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3390\/jcm10091926","article-title":"Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia.","volume":"10","author":"Inaba","year":"2021","journal-title":"J Clin Med"},{"key":"R34-20260817","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","article-title":"Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.","volume":"13","author":"Samra","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R35-20260817","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/jamaoncol.2025.0613","article-title":"Management of adult acute lymphoblastic leukemia: a review.","volume":"11","author":"Kantarjian","year":"2025","journal-title":"JAMA Oncol"},{"key":"R36-20260817","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semcancer.2020.10.013","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities.","volume":"84","author":"Tran","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"Supplement 1","key":"R37-20260817","doi-asserted-by":"crossref","first-page":"7907","DOI":"10.1182\/blood-2024-205478","article-title":"Global, regional and national burden of leukemia, 1990-2021: analysis of data from the Global Burden of Disease Study 2021.","volume":"144","author":"Yun","year":"2024","journal-title":"Blood"},{"key":"R38-20260817","doi-asserted-by":"crossref","first-page":"1542317","DOI":"10.3389\/fmed.2025.1542317","article-title":"Global, regional, and national burden of leukemia, 1990-2021: a systematic analysis of the global burden of disease in 2021.","volume":"12","author":"Chen","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"R39-20260817","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12938-025-01403-7","article-title":"Global, regional, and national burden of acute leukemia and its risk factors from 1990 to 2021 and predictions to 2040: findings from the global burden of disease study 2021.","volume":"24","author":"Han","year":"2025","journal-title":"Biomed Eng Online"},{"key":"R40-20260817","doi-asserted-by":"crossref","first-page":"1525751","DOI":"10.3389\/fpubh.2025.1525751","article-title":"Global, regional, and national burden of children and adolescents with acute lymphoblastic leukemia from 1990 to 2021: a systematic analysis for the global burden of disease study 2021.","volume":"13","author":"Wang","year":"2025","journal-title":"Front Public Health"},{"key":"R41-20260817","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajh.27546","article-title":"Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy.","volume":"100","author":"Hallek","year":"2025","journal-title":"Am J Hematol"},{"key":"R42-20260817","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/cancers12030642","article-title":"Precision medicine management of chronic lymphocytic leukemia.","volume":"12","author":"Moia","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R43-20260817","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00277-014-2217-7","article-title":"Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD).","volume":"94","author":"Pfeil","year":"2015","journal-title":"Ann Hematol"},{"key":"R44-20260817","doi-asserted-by":"crossref","first-page":"885150","DOI":"10.3389\/fonc.2022.885150","article-title":"Distinct age-related clinical features and risk assessment in Chinese with chronic lymphocytic leukemia.","volume":"12","author":"Tian","year":"2022","journal-title":"Front Oncol"},{"key":"R45-20260817","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12939-025-02450-1","article-title":"Healthcare resource allocation and patient choice: evidence from rural China.","volume":"24","author":"Zhao","year":"2025","journal-title":"Int J Equity Health"},{"key":"R46-20260817","doi-asserted-by":"crossref","first-page":"e003714","DOI":"10.1136\/bmjgh-2020-003714","article-title":"Ten-year impacts of China\u2019s rural health scheme: lessons for universal health coverage.","volume":"6","author":"Zhang","year":"2021","journal-title":"BMJ Glob Health"},{"issue":"Suppl 1","key":"R47-20260817","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1186\/1471-2458-12-S1-S8","article-title":"Controlling cost escalation of healthcare: making universal health coverage sustainable in China.","volume":"12","author":"Tang","year":"2012","journal-title":"BMC Public Health"},{"key":"R48-20260817","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hec.3322","article-title":"Health insurance and health care among the mid-aged and older Chinese: evidence from the national baseline survey of CHARLS.","volume":"26","author":"Zhang","year":"2017","journal-title":"Health Econ"},{"key":"R49-20260817","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11899-016-0337-y","article-title":"Treatment of childhood acute lymphoblastic leukemia: prognostic factors and clinical advances.","volume":"11","author":"Vrooman","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"R50-20260817","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOP.0b013e32831f1f24","article-title":"Childhood acute lymphoblastic leukemia: update on prognostic factors.","volume":"21","author":"Vrooman","year":"2009","journal-title":"Curr Opin Pediatr"},{"key":"R51-20260817","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40272-016-0200-6","article-title":"Current management of childhood acute myeloid leukemia.","volume":"19","author":"Rubnitz","year":"2017","journal-title":"Paediatr Drugs"},{"key":"R52-20260817","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.critrevonc.2018.08.008","article-title":"Can we avoid the toxicity of chemotherapy in elderly cancer patients?","volume":"131","author":"Feliu","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"R53-20260817","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.3390\/cancers15082399","article-title":"Optimizing treatment options for newly diagnosed acute myeloid leukemia in older patients with comorbidities.","volume":"15","author":"Oshikawa","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R54-20260817","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.3390\/jcm13216399","article-title":"Evaluating fitness in older acute myeloid leukemia patients: balancing therapy and treatment risks.","volume":"13","author":"Molica","year":"2024","journal-title":"J Clin Med"},{"key":"R55-20260817","doi-asserted-by":"crossref","first-page":"e7150","DOI":"10.1002\/cam4.7150","article-title":"Global, regional, and national burdens of leukemia from 1990 to 2019: a systematic analysis of the global burden of disease in 2019 based on the APC model.","volume":"13","author":"Qu","year":"2024","journal-title":"Cancer Med"},{"key":"R56-20260817","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.12.11.1","article-title":"U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.","volume":"11","author":"Cohen","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R57-20260817","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia.","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"R58-20260817","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nrd2240","article-title":"New therapeutic strategies for the treatment of acute lymphoblastic leukaemia.","volume":"6","author":"Pui","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"R59-20260817","doi-asserted-by":"crossref","first-page":"04248","DOI":"10.7189\/jogh.14.04248","article-title":"Quantifying the impact of disease severity changes on the burden of blindness: a global decomposition analysis.","volume":"14","author":"Chen","year":"2024","journal-title":"J Glob Health"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:01:36Z","timestamp":1786982496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050187"}},"subtitle":["An age-period-cohort and population-based observational analysis of the Global Burden of Disease study 2021"],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":58,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050187","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"2026-03-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}